Tedros Bezabeh1, Omkar B. Ijare1, Nils Albiin2, Matthias Lohr2, Annika Bergquist2, Urban Arnelo2, Ian C. P. Smith1
1National Research Council Institute for Biodiagnostics, Winnipeg, MB, Canada; 2Karolinska University Hospital, Karolinska Institutet, Huddinge, Stockholm, Sweden
Pancreatic cancer is the fourth most common cause of cancer-related deaths with a very low overall 5-year survival rate (<5%). Proteomics-based analyses have detected molecular alterations (K-ras mutations, telomerase reactivation, or methylation of the tumor-suppressor genes) in pancreatic juice samples obtained from patients with pancreatic cancer. However, no definitive molecular markers have been identified yet for the diagnosis of pancreatic cancer. In this study, we have performed 1H-MRS-based biochemical analysis of pancreatic juice samples from different pancreatic diseases including adenocarcinoma. Such analysis will serve as a basis for a metabolomics-based diagnostic approach for the detection of pancreatic cancer.